Brigham and Women's Hospital
brighamandwomens.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,239
Active
286
Phase 3
78
Total enrollment
13,170,677
Pipeline matrix
Showing 40 of 140 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Eplerenone | — | — | 10 | ||||
| Dupilumab | — | — | — | 3 | |||
| Bupivacaine Hydrochloride | — | — | — | — | — | 3 | |
| Trazodone | — | — | — | 3 | |||
| SGLT2 inhibitor | — | — | — | — | 2 | ||
| Rosuvastatin | — | — | — | — | 3 | ||
| Sacubitril-valsartan | — | — | — | — | 2 | ||
| Evolocumab | — | — | — | — | — | 2 | |
| Oral treprostinil (UT-15C) sustained release | — | — | — | — | — | 1 | |
| Valsartan | — | — | — | — | — | 1 | |
| Daridorexant | — | — | — | — | — | 1 | |
| [F-18]FDG | — | — | — | — | — | 1 | |
| Sonotherapy | — | — | — | — | — | 1 | |
| Fremanezumab | — | — | — | — | — | 1 | |
| 18F-DCFPyl | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | — | — | 1 | |
| Fidaxomicin | — | — | — | — | — | 1 | |
| Chlorthalidone | — | — | — | — | — | 1 | |
| Potassium | — | — | — | — | — | 1 | |
| Dapagliflozin (10Mg Tab) along with standard medical therapy | — | — | — | — | — | 1 | |
| Subanesthetic dose intravenous ketamine | — | — | — | — | — | 1 | |
| 18F-rhPSMA-7.3 | — | — | — | — | — | 1 | |
| GLP-1 receptor agonist | — | — | — | — | 3 | ||
| Amlodipine | — | — | — | 3 | |||
| omega-3 fatty acids | — | — | — | — | 13 | ||
| Alvimopan | — | — | — | — | — | 1 | |
| [64Cu]FBP8 PET/MR | — | — | — | — | — | 1 | |
| Cessation of antibiotics | — | — | — | — | — | 1 | |
| multimodal analgesia pathway with up-front small opioid prescription | — | — | — | — | — | 1 | |
| multimodal analgesia pathway without up-front small opioid prescription | — | — | — | — | — | 1 | |
| pre-implementation baseline including opioid | — | — | — | — | — | 1 | |
| [68Ga]CBP8 PET/MRI | — | — | — | — | — | 1 | |
| multimodal analgesia regimen without suzetrigine | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| BRS201 | — | — | — | — | — | 3 | |
| Tirzepatide | — | — | — | — | 10 | ||
| Acetazolamide | — | — | — | — | — | 3 | |
| Normal saline | — | — | — | — | — | 3 | |
| MIB-626 | — | — | — | — | 3 | ||
| Semaglutide | — | — | — | — | 10 |
100 more active programs hidden
Next readouts
- 2018-11-10
- 2022-11-30
- 2023-07-21
- 2023-09-30
- 2023-12-01
- 2024-06-04
- 2024-08-26
- 2024-11-21
- 2024-12-31
- 2025-05-15
Top conditions
- Hypertension48
- Asthma36
- Obesity32
- Heart Failure27
- Diabetes26
- Cardiovascular Diseases21
- Obstructive Sleep Apnea20
- Rheumatoid Arthritis20
Frequently asked questions about Brigham and Women's Hospital
- How many clinical trials does Brigham and Women's Hospital have on ClinicalTrials.gov?
- Brigham and Women's Hospital is listed as the lead sponsor on 1,239 clinical trials in ClinicalTrials.gov, 286 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Brigham and Women's Hospital's trials are in Phase 3?
- 78 of Brigham and Women's Hospital's trials are in Phase 3, spread across 140 active drug programs.
- What therapeutic areas does Brigham and Women's Hospital focus on?
- Brigham and Women's Hospital's most-studied conditions on ClinicalTrials.gov are Hypertension, Asthma, Obesity, Heart Failure, Diabetes.
- When are Brigham and Women's Hospital's next clinical trial readouts?
- Brigham and Women's Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Vitamin D and Omega-3 Trial (VITAL)”, expected around 2018-11-10.